ASX:OCCPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Orthocell Ltd
$0.735
$0.010 (1.34%)
Day Range
$0.735 – $0.760
52 Week Range
$0.700 – $1.600
Volume
233.15K
Avg Volume (10D)
256.05K
Market Cap
$200.11M
Price Chart
Market Statistics
Open$0.755
Previous Close$0.745
Day High$0.760
Day Low$0.735
52 Week High$1.600
52 Week Low$0.700
Valuation
Market Cap200.11M
Shares Outstanding272.25M
Price to Book4.94
Trading Activity
Volume233.15K
Value Traded173.70K
Bid$0.735 × 9,592
Ask$0.750 × 30,522
Performance
1 Day-1.32%
5 Day0.00%
13 Week-8.54%
52 Week-40.48%
YTD-30.88%
Technical Indicators
RSI (14)36.31
50-Day SMA$0.837
200-Day SMA$1.003
Latest News
Biotechnology
Orthocell Secures Access to 221 US Military & VA Medical Centres for Remplir
Orthocell wins access to 221 US DoD/VA centres for Remplir, a major US market expansion as HY26 revenue hits A$6.2m and cash sits at A$49.4m.
Biotechnology
Orthocell's Remplir Device Used in 23 Ukrainian Soldier Surgeries, Validating Field Utility
Orthocell's Remplir validated after 23 Ukrainian surgeries, boosting defence-market traction and global expansion; HY26 revenue +49%, cash ~A$49m.
Biotechnology
Orthocell Appoints Exclusive Remplir Distributor Ahead of UK Rollout
Orthocell names LEDA Orthopaedics exclusive UK distributor for Remplir ahead of regulatory approval, signaling rapid UK rollout and market prep.
Biotechnology
Orthocell Reports Accelerated Adoption of Remplir Nerve Repair Technology by Australian Surgeons
Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from peripheral nerve injury.